Carboplatin Pharmachemie Drug Interactions

Carboplatin/Bone Marrow Suppressants: Concurrent use of carboplatin with other myelosuppressive therapies may necessitate changes in the dosage or frequency of carboplatin administration in order to minimize additive myelosuppressive effects.
Carboplatin/Cisplatin: Incidence of carboplatin-induced neurotoxicity or ototoxicity is increased in patients previously treated with cisplatin; use of carboplatin worsens pre-existing cisplatin-induced neurotoxicity or ototoxicity.
Carboplatin/Nephrotoxic Drugs: Carboplatin has limited nephrotoxic potential, but concomitant treatment with nephrotoxic compounds may increase or exacerbate toxicity due to carboplatin induced changes in renal clearance.
Carboplatin/Vaccines, Killed Virus: Because normal defense mechanisms may be suppressed by carboplatin therapy, the patient's antibody response to the vaccine may be decreased. The interval between discontinuation of medications that cause immunosuppression and restoration of the patient's ability to respond to the vaccine depends on the intensity and type of immunosuppression-causing medication used, the underlying disease, and other factors; estimates vary from 3 months to 1 year.
Carboplatin Vaccines, Live Virus: Because normal defense mechanisms may be suppressed by carboplatin therapy, concurrent use with a live virus vaccine may potentiate the replication of the vaccine virus, may increase the adverse effects of the vaccine virus, and/or may decrease the patient's antibody response to the vaccine; immunization of these patients should be undertaken only with extreme caution after careful review of the patient's hematologic status and only with the knowledge and consent of the physician managing the carboplatin therapy. The interval between discontinuation of medications that cause immunosuppression and restoration of the patient's ability to respond to the vaccine depends on the intensity and type of immunosuppression-causing medication used, the underlying disease, and other factors; estimates vary from 3 months to 1 year.
Patients with leukemia in remission should not receive live virus vaccine until at least 3 months after their last chemotherapy. In addition, immunization with oral polio-virus vaccine should be postponed in persons in close contact with the patient, especially family members.